UCB Pharma
UCB | Inspired by patients. Driven by science..
| EUR | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 8 % | (5 %) | (5 %) | 17 % | 10 % | 13 % | 12 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 27 % | 23 % | 24 % | 25 % | 30 % | 34 % | 37 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 18 % | 8 % | 7 % | 17 % | 14 % | 18 % | 21 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 28 % | 30 % | 31 % | 29 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
UCB is a global biopharmaceutical company headquartered in Brussels, Belgium, with approximately 9000 employees across 40 countries. The company focuses on developing treatments for severe diseases, particularly in the fields of neurology and immunology. UCB connects with patients and their families to gain insights that drive innovation and the development of new therapies. The company invests more than 25% of its revenue into scientific research to address unmet patient needs. UCB's business model revolves around the discovery, development, and commercialization of novel molecules, contributing to its €5.3 billion global revenue in 2023. The company serves patients worldwide, aiming to transform lives through its commitment to science and patient care.
Keywords: biopharmaceutical, neurology, immunology, severe diseases, scientific research, global, patients, therapies, revenue, innovation.
Tech stack
Investments by UCB Pharma
Edit
